Maegim한국어

페니트리움바이오

187660KOSDAQSector: Pharma & Biotech
₩4,150 5.06%Market cap ₩230.2BAs of Jul 21, 2026 close · updated once daily
D
Grade D25.5 ptsTop 92% of 2,523 stocks
Financial strength
27.2
Price attractiveness
23.6

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Growth momentum not rated — will be included automatically as data accumulates

1

Financial strength

27.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
52.3%
Below median · Top 50.2% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
89.1%
Below median · Top 80.7% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-79.5%
Below median · Top 71.8% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-68.9%
Below median · Top 88.4% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original

3

Price attractiveness

23.6
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 65.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
10.70x
Below median · Top 87.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15